Catalyst Biosciences Inc (NASDAQ:CBIO) major shareholder James E. Flynn sold 52,461 shares of the business’s stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $30.87, for a total transaction of $1,619,471.07. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Catalyst Biosciences Inc (NASDAQ CBIO) opened at $28.03 on Friday. Catalyst Biosciences Inc has a 52-week low of $3.11 and a 52-week high of $37.00.
A number of institutional investors have recently added to or reduced their stakes in the business. Ardsley Advisory Partners acquired a new position in Catalyst Biosciences during the 4th quarter worth $205,000. Renaissance Technologies LLC increased its holdings in shares of Catalyst Biosciences by 6.5% during the 4th quarter. Renaissance Technologies LLC now owns 355,373 shares of the biopharmaceutical company’s stock worth $4,847,000 after purchasing an additional 21,600 shares during the period. Bank of New York Mellon Corp bought a new position in shares of Catalyst Biosciences during the 2nd quarter worth about $107,000. Geode Capital Management LLC bought a new position in shares of Catalyst Biosciences during the 4th quarter worth about $379,000. Finally, Vanguard Group Inc. increased its holdings in shares of Catalyst Biosciences by 294.1% during the 2nd quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock worth $204,000 after purchasing an additional 32,621 shares during the period. 29.64% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This report was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3252704/insider-selling-catalyst-biosciences-inc-cbio-major-shareholder-sells-52461-shares-of-stock.html.
About Catalyst Biosciences
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.